Synergy Pharmaceuticals

 
Stock Quotes for Synergy Pharmaceuticals top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for sgyp investment picks

 
News Articles for Synergy Pharmaceuticals top ^
2013/8/8
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) , a developer of new drugs to treat gastrointestinal diseases and disorders, today announced the planned spin-off of its FV-100 assets into a separate publicly traded company.
Sign-up for Synergy Pharmaceuticals’ Subsidiary Files Form 10 for Planned Spin-Off of FV-100 Assets investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). The multi-center, randomized, double-blind clinical trial will compare a 4-week, dose-ranging regimen of SP-333 (1.0, 3.0 and 6.0mg) against placebo in adult patients taking opioid analgesics for chronic, non-cancer pain for at least three months.
Sign-up for Synergy Pharmaceuticals Initiates Phase 2 Study of SP-333 in Patients with Opioid-Induced Constipation investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced plans to move forward this quarter with SP-333, its proprietary next-generation guanylate cyclase-C (GC-C) agonist, into a phase 2 study for the treatment of opioid-induced constipation (OIC). “The start of this trial represents the ongoing progress being made in the clinical development of our novel GC-C agonist platform in multiple gastrointestinal indications,” said Dr.
Sign-up for Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation investment picks
2013/11/13
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation (CIC). The pivotal phase 3 trial is a randomized, double-blind, clinical trial to compare a 12-week, dose-ranging regimen of plecanatide (3.0 and 6.0mg) against placebo in adult patients with CIC.
Sign-up for Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) today announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on Synergy’s drug plecanatide for the treatment of chronic idiopathic constipation (CIC). At that meeting, agreement was reached on the clinical development plan.
Sign-up for Synergy Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for Plecanatide in Chronic Idiopathic Constipation investment picks
2013/11/12
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the third quarter ended September 30, 2013.
Sign-up for Synergy Pharmaceuticals Reports Third Quarter 2013 Financial Results investment picks
2014/3/17
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013.
Sign-up for Synergy Pharmaceuticals Reports 2013 Fourth Quarter and Full-Year Financial Results investment picks
2013/8/9
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) , a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the second quarter ended June 30, 2013.
Sign-up for Synergy Pharmaceuticals Reports Second Quarter 2013 Financial Results investment picks
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) today announced a poster presentation on SP-333, its next-generation guanylate cyclase-C (GC-C) agonist in development for the treatment of gastrointestinal (GI) conditions, will be featured at the 17 th Neurogastroenterology & Motility Scientific Meeting being held September 20-22, 2013 at the Hyatt Regency Resort & Spa in Huntington Beach, California.
Sign-up for Synergy Pharmaceuticals Announces SP-333 Data Presentation at the 17th Neurogastroenterology & Motility Scientific Meeting investment picks
2013/11/8
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S.
Sign-up for Synergy Pharmaceuticals to Present at 2013 Credit Suisse Healthcare Conference investment picks
2013/8/12
Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP) , a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S.
Sign-up for Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference investment picks
2014/3/13
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of Marino Garcia as Senior Vice President, Corporate Development.
Sign-up for Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development investment picks
2013/12/24
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C). The clinical trial is being conducted at approximately 70 sites in the United States and includes four doses of plecanatide (0.3mg, 1.0mg, 3.0mg, 9.0mg) plus a placebo arm, taken once daily over a period of 12 weeks.
Sign-up for Synergy Pharmaceuticals Closes Enrollment for Plecanatide Phase 2b Trial in Patients with IBS-C investment picks
2014/2/3
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S.
Sign-up for Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences investment picks
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S.
Sign-up for Synergy Pharmaceuticals to Present at Aegis Capital 2013 Healthcare Conference investment picks
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for gastrointestinal (GI) disorders, will take place at two scientific meetings this month.
Sign-up for Synergy Pharmaceuticals Announces Data Presentations on Plecanatide and SP-333 at Two Scientific Meetings investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced listing of the company’s common stock has been transferred to the NASDAQ Global Select Market, the highest of the three market tiers at NASDAQ.
Sign-up for Synergy Pharmaceuticals Named to NASDAQ Global Select Market investment picks
2014/2/19
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary lecture entitled, “Cyclic GMP: Understanding its Evolution and Clinical Implications in Gastroenterology,” during the Southern Gut Club meeting being held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm (EST). Cyclic GMP is a key intracellular mediator activated by the intestinal guanylate cyclase-C (GC-C) receptor and is responsible for initiating downstream GC-C signaling essential for maintenance of electrolytes and fluid transport as well as in regulation of homeostasis in epithelial cells lining the GI mucosa.
Sign-up for Synergy Pharmaceuticals’ Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Synergy Pharmaceuticals
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Syndicated Credit Facility  |  Next: SYNERGY RESOURCES